Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723639 | 0.89 | ALDH1A1 (0.52) | ALDH1A1ALPLLMNASMN1; SMN2HTT | |
| SCHEMBL23723719 | 0.85 | KMT2A (0.49) | ALDH1A1ALPLLMNAHTTKMT2A | |
| SCHEMBL23723623 | 0.84 | KMT2A (0.61) | ALDH1A1ALPLLMNASMN1; SMN2HTT | |
| SCHEMBL30132076 | 0.83 | ALDH1A1 (0.39) | ALDH1A1ALPLKMT2AALDH1A2ALDH1A3 | |
| SCHEMBL23723749 | 0.83 | ALDH1A1 (0.39) | ALDH1A1ALPLKMT2AALDH1A2ALDH1A3 | |
| SCHEMBL30368715 | 0.81 | KMT2A (0.45) | ALDH1A1ALPLLMNASMN1; SMN2HTT | |
| SCHEMBL30132070 | 0.76 | ALDH1A1 (0.57) | ALDH1A1ALPLLMNASMN1; SMN2HTT | |
| SCHEMBL23723622 | 0.76 | ALDH1A1 (0.57) | ALDH1A1ALPLLMNASMN1; SMN2HTT | |
| SCHEMBL23723853 | 0.76 | TNKS (0.40) | ALDH1A1ALPLLMNAKMT2AMEN1 | |
| SCHEMBL23750016 | 0.75 | GAA (0.39) | ALDH1A1KMT2AMEN1ALDH1A2ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | ALDH1A1 796/4885ALPL 653/4885LMNA 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.